Wednesday, July 29, 2015 11:00:16 AM
In looking at the consensus numbers, the sell-side analysts covering the stock have a mean target price of $6.5 for AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). This number is the mean estimate from the 6 research brokerages that recently issued reports on the firm.
According to Wall Street, AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) is expected to report earnings per share for the current fiscal quarter of $-0.26. This is the consensus mean estimate based on the individual covering sell-side analysts’ reported numbers. The company last reported earnings for the period ending on 2015-03-31 of $-0.27.
The average recommendation is the arithmetical average of the individual analyst ratings contributed by sell-side research to produce a Consensus Analyst Rating for each stock. On a scale of 1 to 5 where 1 represents a Strong Buy and 5 represents a Strong Sell, has the equity is ranked 2.57 based on 6 broker recommendations. Of the 6 analyst estimates, the most bullish sees the stock reaching $14 within the next 12 months while the most bearish analyst sees the stock at $3 within the year.
Taking a look at the long term growth prospects of the company, sell-side analysts have a consensus mean earnings per share estimate for the current year of $N/A. The high end estimate for this time frame is $N/A with the low being $N/A.
AcelRx Pharmaceuticals, Inc. is a United States-based Pharmaceutical Company, which develops and commercializes therapies for the treatment of pain. The Company’s products include ARX-01 Sufentanil NanoTab PCA System, to solve the problems associated with post-operative intravenous patient-controlled analgesia (IV PCA); ARX-02 Sufentanil NanoTab BTP Management System is a treatment option for cancer patients who suffer from breakthrough pain (BTP). ARX-03 Sufentanil/Triazolam NanoTab, provides non-invasive mild sedation, anxiety reduction and pain relief; and ARX-04 Sufentanil Acute Pain NanoTab, is a sublingual sufentanil product candidate designed to provide a non-invasive, fast-onset treatment of patients with moderate-to-severe acute pain, both on the battlefield and in civilian settings of trauma or injury.
Recent TLPH News
- Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference • PR Newswire (US) • 09/05/2024 08:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:22:55 PM
- Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit • PR Newswire (US) • 08/19/2024 12:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/14/2024 09:22:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:12:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:10:32 PM
- Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 08/14/2024 08:01:00 PM
- Talphera to Host Second Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, August 14, 2024 • PR Newswire (US) • 08/05/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 09:19:26 PM
- Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 05/20/2024 09:25:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/20/2024 09:22:15 PM
- Talphera to Participate at A.G.P. Virtual Healthcare Conference • PR Newswire (US) • 05/16/2024 09:45:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 09:00:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:15:28 PM
- Talphera Announces First Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 05/14/2024 08:05:00 PM
- Talphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024 • PR Newswire (US) • 05/02/2024 08:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 10:00:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:11:29 PM
- Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update • PR Newswire (US) • 03/06/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 01:55:33 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 01:54:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 01:53:08 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 12:35:13 PM
- Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members • PR Newswire (US) • 03/01/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 02:06:44 AM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM